Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.

Ding L, Li R, Sun R, Zhou Y, Zhou Y, Han X, Cui Y, Wang W, Lv Q, Bai J.

Cell Cycle. 2017 Aug 18;16(16):1547-1555. doi: 10.1080/15384101.2017.1346760. Epub 2017 Aug 3.

PMID:
28771075
2.

MYC Modulation around the CDK2/p27/SKP2 Axis.

Hydbring P, Castell A, Larsson LG.

Genes (Basel). 2017 Jun 30;8(7). pii: E174. doi: 10.3390/genes8070174. Review.

3.

Nitidine chloride inhibited the expression of S phase kinase-associated protein 2 in ovarian cancer cells.

Mou H, Guo P, Li X, Zhang C, Jiang J, Wang L, Wang Q, Yuan Z.

Cell Cycle. 2017 Jul 18;16(14):1366-1375. doi: 10.1080/15384101.2017.1327490. Epub 2017 Jun 8.

PMID:
28594256
4.

Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells.

Feng S, Wang Y, Zhang R, Yang G, Liang Z, Wang Z, Zhang G.

Onco Targets Ther. 2017 May 2;10:2377-2388. doi: 10.2147/OTT.S130055. eCollection 2017.

5.

Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.

Ruan D, He J, Li CF, Lee HJ, Liu J, Lin HK, Chan CH.

Oncogene. 2017 Jul 27;36(30):4299-4310. doi: 10.1038/onc.2017.64. Epub 2017 Mar 27.

6.

DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression.

Barr AR, Cooper S, Heldt FS, Butera F, Stoy H, Mansfeld J, Novák B, Bakal C.

Nat Commun. 2017 Mar 20;8:14728. doi: 10.1038/ncomms14728.

7.

The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor.

Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, Liu P, Li H, Tan M, Xiong X, Sun Y.

Nat Commun. 2017 Jan 16;8:14002. doi: 10.1038/ncomms14002.

8.

Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells.

Wang N, Wang X, Tan HY, Li S, Tsang CM, Tsao SW, Feng Y.

Int J Mol Sci. 2016 Nov 15;17(11). pii: E1899.

9.

Structural Chromosomal Rearrangements Require Nucleotide-Level Resolution: Lessons from Next-Generation Sequencing in Prenatal Diagnosis.

Ordulu Z, Kammin T, Brand H, Pillalamarri V, Redin CE, Collins RL, Blumenthal I, Hanscom C, Pereira S, Bradley I, Crandall BF, Gerrol P, Hayden MA, Hussain N, Kanengisser-Pines B, Kantarci S, Levy B, Macera MJ, Quintero-Rivera F, Spiegel E, Stevens B, Ulm JE, Warburton D, Wilkins-Haug LE, Yachelevich N, Gusella JF, Talkowski ME, Morton CC.

Am J Hum Genet. 2016 Nov 3;99(5):1015-1033. doi: 10.1016/j.ajhg.2016.08.022. Epub 2016 Oct 13.

10.

Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells.

Su J, Zhou X, Wang L, Yin X, Wang Z.

Am J Cancer Res. 2016 Sep 1;6(9):1949-1962. eCollection 2016.

11.

Cyclin D1, cancer progression, and opportunities in cancer treatment.

Qie S, Diehl JA.

J Mol Med (Berl). 2016 Dec;94(12):1313-1326. Epub 2016 Oct 2. Review.

PMID:
27695879
12.

Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.

Malek E, Abdel-Malek MA, Jagannathan S, Vad N, Karns R, Jegga AG, Broyl A, van Duin M, Sonneveld P, Cottini F, Anderson KC, Driscoll JJ.

Leukemia. 2017 Mar;31(3):645-653. doi: 10.1038/leu.2016.258. Epub 2016 Sep 28.

13.

The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity.

Xu Y, Zhao F, Qiu Q, Chen K, Wei J, Kong Q, Gao B, Melo-Cardenas J, Zhang B, Zhang J, Song J, Zhang DD, Zhang J, Fan Y, Li H, Fang D.

Nat Commun. 2016 Jul 15;7:12073. doi: 10.1038/ncomms12073.

14.

SCFFbl12 Increases p21Waf1/Cip1 Expression Level through Atypical Ubiquitin Chain Synthesis.

Tsuruta F, Takebe A, Haratake K, Kanemori Y, Kim J, Endo T, Kigoshi Y, Fukuda T, Miyahara H, Ebina M, Baba T, Chiba T.

Mol Cell Biol. 2016 Jul 29;36(16):2182-94. doi: 10.1128/MCB.00174-16. Print 2016 Aug 15.

15.

Recent advances in SCF ubiquitin ligase complex: Clinical implications.

Zheng N, Zhou Q, Wang Z, Wei W.

Biochim Biophys Acta. 2016 Aug;1866(1):12-22. doi: 10.1016/j.bbcan.2016.05.001. Epub 2016 May 5. Review.

16.

Drugging the undruggables: exploring the ubiquitin system for drug development.

Huang X, Dixit VM.

Cell Res. 2016 Apr;26(4):484-98. doi: 10.1038/cr.2016.31. Epub 2016 Mar 22. Review.

17.

Expressions and clinical significance of factors related to giant cell tumor of bone.

Li C, Zheng X, Ghert M, Li H, Wang B, Feng Y.

Int J Clin Exp Med. 2015 Dec 15;8(12):22509-14. eCollection 2015.

18.

Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Zheng N, Wang Z, Wei W.

Int J Biochem Cell Biol. 2016 Apr;73:99-110. doi: 10.1016/j.biocel.2016.02.005. Epub 2016 Feb 6. Review.

19.

Broad and potent antiviral activity of the NAE inhibitor MLN4924.

Le-Trilling VT, Megger DA, Katschinski B, Landsberg CD, Rückborn MU, Tao S, Krawczyk A, Bayer W, Drexler I, Tenbusch M, Sitek B, Trilling M.

Sci Rep. 2016 Feb 1;6:19977. doi: 10.1038/srep19977.

20.

Dysregulation of ubiquitin ligases in cancer.

Qi J, Ronai ZA.

Drug Resist Updat. 2015 Nov;23:1-11. doi: 10.1016/j.drup.2015.09.001. Epub 2015 Sep 28. Review.

Supplemental Content

Support Center